Last reviewed · How we verify
Timentin
Timentin is a Small molecule drug developed by Osprey Medical, Inc. It is currently in Phase 2 development. Also known as: Ticarcillin and Clavulanate.
Timentin, also known as ticarcillin/clavulanic acid, is a combination antibiotic consisting of ticarcillin and clavulanic acid, a β-lactamase inhibitor. It is a small molecule modality used to treat various infections, including systemic infections, pelvic infections, and infections in individuals with diabetes.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Timentin |
|---|---|
| Also known as | Ticarcillin and Clavulanate |
| Sponsor | Osprey Medical, Inc |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio) (PHASE1)
- The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial (NA)
- Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD (PHASE2, PHASE3)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis (PHASE4)
- An Investigational Agent for the Treatment of Complicated Intra-Abdominal Infections or Acute Pelvic Infections (0826-038) (PHASE2)
- Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients (PHASE2)
- WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Timentin CI brief — competitive landscape report
- Timentin updates RSS · CI watch RSS
- Osprey Medical, Inc portfolio CI
Frequently asked questions about Timentin
What is Timentin?
Who makes Timentin?
Is Timentin also known as anything else?
What development phase is Timentin in?
Related
- Manufacturer: Osprey Medical, Inc — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Ticarcillin and Clavulanate
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing